Latest Headlines

Latest Headlines

Lundbeck teams with Otsuka on Alzheimer's vaccine development

The vaccine, which is designed to work through early inhibition of amyloid beta depositions, is due to enter Phase I trials next year.

Activist investor fumes over Otsuka bid for Astex

It's a "he said, she said" situation over the true value of Astex Pharmaceuticals. An activist shareholder has thrown up a roadblock for a proposed $886 million bid from Otsuka that it thinks is too low, accusing Astex of failing to reach out to all potential bidders--claims the company denies.

Glaxo, Roche, J&J and others score backing on big day for EU regulator

Friday, the EU's Committee for Medicinal Products for Human Use (CHMP) recommended 11 new drugs for a variety of diseases--the most nods it's given in a single meeting all year.

Otsuka bags Astex cancer drug programs, R&D ops for $886M

Just a few days after Astex reported positive mid-stage data on a lead cancer therapy, Japan's Otsuka has snapped up the U.S. biotech and its slate of experimental cancer drugs for $886 million cash. Astex shares soared yesterday afternoon as the news spread ahead of the official announcement.

Lundbeck, Otsuka tout improved cognition in mid-stage Alzheimer's study

Lundbeck and Otsuka are quickly ramping up a 3,000-patient Phase III study for an experimental Alzheimer's drug after claiming success in improving cognition among a group of patients taking the treatment alongside donepezil for 24 weeks in a Phase II trial.

Headed into PhIII, Lundbeck scores $825M Alzheimer's drug pact with Otsuka

Building on an earlier alliance, Otsuka has gained co-development and co-promotion rights in the U.S., Japan and Europe for Lu AE58054, an experimental Alzheimer's drug now in position for a looming pivotal program.

GW Pharma IDs promising epilepsy drug in cannabis

GW Pharmaceuticals, the U.K. biotech which is commercializing a cannabis-based drug for multiple sclerosis, says their research collaboration with Otsuka has produced a promising new drug candidate for epilepsy.

Lundbeck, Otsuka scramble to get antipsychotic back on FDA track

Lundbeck and its partner Otsuka have put their bid for an approval of their long-acting version of the antipsychotic drug Abilify back on the regulatory track. The partners on aripiprazole say that the FDA has accepted their resubmission for the treatment and set a PDUFA deadline for the end of February in 2013.

UPDATED: FDA denies Otsuka and Lundbeck's antipsychotic drug

U.S. regulators have delayed the potential launch of a once-monthly version of the blockbuster antipsychotic Abilify. Otsuka Pharmaceutical and partner H. Lundbeck broke the bad news today that the FDA handed the companies a complete response letter (CRL), saying deficiencies were uncovered in an inspection of a third-party supplier of sterile water for making the drug.

Otsuka cracks tough TB cases with experimental drug

As drug-resistant cases of tuberculosis rage, Otsuka has impressed doctors with a developmental drug that has shown an ability to wipe out strains of the airborne bug that have immunity to existing treatments.